How to Get Low-Dose Naltrexone in Washington

What Low-Dose Naltrexone Is, and What It Is Not

Naltrexone hydrochloride is an opioid receptor antagonist. At the FDA-approved dose of 50 mg daily (oral, brand ReVia and generics) or as a monthly 380 mg extended-release injection (Vivitrol), it is indicated for opioid use disorder and alcohol use disorder, and it carries a boxed warning for hepatotoxicity [1]. "Low-dose naltrexone" is the same active ingredient prescribed off-label at roughly one-tenth to one-thirtieth of that dose, 1.5 to 4.5 mg, usually taken at bedtime. No manufacturer sells naltrexone at this strength, so every LDN prescription is filled by a compounding pharmacy rather than a retail chain pharmacy stocking a commercial bottle.

The proposed mechanism at low doses differs from the approved use: rather than sustained opioid blockade, transient nightly blockade is theorized to upregulate endogenous opioid peptides and reduce pro-inflammatory cytokines such as TNF-alpha and IL-6 [5]. This is a plausible, mechanistically described hypothesis, not an established mechanism confirmed in large trials.

Naltrexone at any dose, including LDN, is not a controlled substance under federal or Washington law, and Washington does not impose an in-person visit requirement before prescribing a non-controlled medication. That combination is why telehealth access to LDN is legally straightforward in Washington even though the underlying clinical evidence for LDN itself is still limited to small trials.

Who Can Legally Prescribe LDN in Washington

Washington does not create a separate rule for LDN. Any prescriber with active prescriptive authority in the state can write the prescription, subject to normal scope-of-practice limits:

• Physicians (MD/DO): full independent prescriptive authority through the Washington Medical Commission.
• Advanced Registered Nurse Practitioners (ARNPs): independent prescriptive authority under RCW 18.79.250, with no collaborative physician agreement required [6].
• Physician Assistants (PA-Cs): prescribe under a delegation agreement with a supervising physician.

Because naltrexone is not scheduled, none of the additional DEA transfer or in-person examination rules that apply to controlled substances apply here. This is the reason telehealth-only LDN consultations, including through platforms like HealthRX.com, are legally viable for Washington residents, including those in counties with few local prescribers experienced in LDN.

How a Telehealth LDN Visit Typically Proceeds

A typical telehealth path has four stages, though the exact sequence varies by clinic:

1. Intake. A medical history covering your diagnosis, current medications, and any opioid use. Opioid screening is clinically necessary: naltrexone at any dose can precipitate acute withdrawal in a person who is physically dependent on opioids, so most protocols require a period of confirmed opioid abstinence, commonly discussed as 7 to 10 days, before starting.
2. Consultation. The provider assesses whether LDN is a reasonable off-label option for your condition and may order baseline labs.
3. Prescription. If appropriate, an e-prescription for compounded capsules, usually starting at 1.5 mg nightly with a step-up schedule, is sent to a licensed 503A compounding pharmacy.
4. Fulfillment. The pharmacy compounds and ships the capsules. Turnaround time depends on the specific pharmacy's workload and shipping method; ask the pharmacy directly for its current estimate rather than assuming a fixed number of days.

Compounding Pharmacies: the 503A Pathway

LDN is not available as a finished commercial product at 1.5 to 4.5 mg, so a 503A compounding pharmacy prepares it against your individual prescription. This is distinct from a 503B outsourcing facility, which produces compounded drugs in bulk without a patient-specific prescription; 503A is the standard pathway for LDN [7].

Before using any compounding pharmacy for LDN, it is reasonable to verify:

• An active pharmacy license in Washington (or a valid non-resident pharmacy license if the pharmacy ships from another state)
• Compliance with USP <795> non-sterile compounding standards
• Independent quality accreditation such as PCAB, where available
• A pharmacist or staff member willing to communicate directly with your prescriber about dose changes

Washington maintains its own pharmacy practice regulations governing compounding, in addition to the federal 503A framework. If you need the exact current state rule citation, confirm it with the Washington State Board of Pharmacy rather than relying on a secondhand reference, since administrative code sections are renumbered periodically.

Insurance and Medicaid: What Is Established and What Requires Direct Verification

This is the area of the page most likely to go stale, and the area where a generic guide is least reliable.

What is reasonably stable: Washington Apple Health (Medicaid) generally requires prior authorization for off-label drug uses, and LDN, being off-label at every dose below 50 mg, would ordinarily fall into that category. Private insurers commonly treat compounded medications as non-formulary, which is a standard industry practice, not something specific to Washington.

What is not established here and needs direct confirmation from your plan: the current prior authorization criteria, current processing timelines, and which specific Washington insurers cover compounded LDN and under what benefit category. Plan formularies, medical policies, and processing standards change, and none of the source material available for this article documents Washington-specific insurer rules or Washington Medicaid turnaround times. Do not treat any number you see elsewhere online as current without checking directly with the Washington Health Care Authority or your plan's member services line.

Outside Washington, a survey of 107 patients prescribed LDN found that only about 17% received full insurance reimbursement, while roughly 71% paid entirely out of pocket [8]. That data comes from Norway and describes a different health system, so it should be read as an illustration that low insurance reimbursement for compounded LDN is common internationally, not as a Washington-specific statistic.

Cash-pay pricing for compounded LDN is commonly discussed in the range of tens of dollars per month, but exact pharmacy pricing is volatile, varies by pharmacy and dose, and should be confirmed with the specific compounding pharmacy at the time of your prescription rather than treated as fixed.

What Labs Are Commonly Requested Before Starting

No professional guideline mandates a specific lab panel before starting LDN. In clinical practice, many prescribers order baseline labs consistent with the 50 mg formulation's hepatotoxicity warning, even though controlled trials at 1.5 to 4.5 mg have not documented liver injury attributable to LDN [1][2][3]:

• Comprehensive metabolic panel, including liver enzymes (AST, ALT), as a baseline given the boxed hepatotoxicity warning that applies to the approved dose
• Complete blood count, particularly relevant when the indication is autoimmune
• Thyroid panel when the indication involves Hashimoto's thyroiditis or prominent fatigue
• Inflammatory markers (CRP, ESR) as a baseline for tracking response in inflammatory conditions
• Urine drug screen, used by some clinics to confirm absence of active opioid use before starting

These are common clinical practices described in published trial protocols and general prescribing caution, not a formal society guideline. If your prescriber orders a different panel or skips labs entirely, that is within normal practice variation, not necessarily a red flag.

What the Clinical Trial Evidence Actually Shows

The evidence base for LDN remains built on small trials and observational studies. No large, multicenter Phase III randomized trial for any LDN indication has been published.

Fibromyalgia. A 2009 single-blind crossover pilot in 10 women found a 32.5% reduction in fibromyalgia symptom severity with LDN 4.5 mg versus placebo over 8 weeks [2]. A 2013 double-blind, placebo-controlled crossover RCT in 31 patients confirmed a 28.8% reduction in daily pain (P = 0.016), with reduced mechanical and thermal pain sensitivity [3]. Both trials are small; neither should be read as definitive.

Crohn's disease. A 2007 pilot of LDN 4.5 mg in 17 patients with active Crohn's disease reported clinical response in 15 of 17 and remission in 11 of 17 by CDAI criteria after 12 weeks [9]. A subsequent double-blind RCT (N = 40) found 78% of LDN patients achieved a 70-point CDAI decline versus 28% on placebo (P = 0.009), with endoscopic improvement in some patients [10].

Multiple sclerosis. A 2008 pilot RCT in primary progressive MS and a separate cross-sectional survey of 215 MS patients reported favorable but non-definitive signals, largely on quality-of-life measures rather than confirmed disease-modifying endpoints [11].

Sarcoidosis. LDN has also been explored in small case-based work for sarcoidosis [12]. This body of evidence is preliminary, and any claim about LDN's effect on sarcoidosis specifically should be treated as unverified pending larger controlled study; discuss this indication directly with a clinician rather than inferring efficacy from the fibromyalgia or Crohn's data above.

Safety signal across trials. Reported side effects at 1.5 to 4.5 mg are mostly mild: vivid dreams (reported by roughly a third of participants in the Younger fibromyalgia trials), transient headache, and occasional nausea in the first week [2][3]. No serious adverse event attributable to LDN has been reported in these published trials, though the total number of patients studied remains small relative to widely used medications.

No major specialty body, including the Endocrine Society, the American College of Rheumatology, or the American Academy of Pain Medicine, has published a formal clinical practice guideline recommending LDN for any of these conditions as of this writing. Off-label prescribing here reflects individual clinical judgment informed by early trial data, not a guideline-endorsed standard of care.

Titration and What Patients Commonly Report Over 12 Weeks

A frequently used titration schedule starts at 1.5 mg nightly for about 2 weeks, increases to 3.0 mg for about 2 weeks, then reaches a target of 4.5 mg nightly by roughly week 5. This schedule reflects common clinical practice rather than a single validated protocol.

Bedtime dosing is theorized to align the drug's several-hour opioid blockade with a nighttime endorphin cycle, which may prompt compensatory receptor and endorphin changes by morning [5]. This remains a proposed mechanism, not a directly proven pharmacodynamic sequence in humans.

In the Younger fibromyalgia trials, participants who responded typically reported pain changes beginning around week 4 [3]. Patients who see no benefit after roughly 12 weeks at full dose are generally advised by prescribers to discontinue; naltrexone does not produce physical dependence, so it does not require a taper to stop.

Transferring an Out-of-State LDN Prescription

Because naltrexone is not a controlled substance, none of the DEA-specific transfer restrictions that apply to scheduled drugs apply here. In practice, the simplest route is usually not a formal "transfer" at all: ask your existing prescriber to send a fresh electronic prescription to a Washington-licensed 503A pharmacy, since compounding formulations, fillers, and capsule sizes can differ between pharmacies and complicate a literal transfer. If your current prescriber is not licensed in Washington, you will need a Washington-licensed provider, which a short telehealth visit can typically accomplish, referencing your prior LDN history.

Evidence-Boundary Verification Checklist

Some facts about LDN access in Washington are stable and federally or clinically anchored. Others are date-sensitive and controlled by an insurer, pharmacy, or agency that can change its position without notice. Confusing the two is the most common way this kind of guide goes stale. Use this checklist to sort a claim before acting on it.

If a claim falls in the bottom half of this table, treat any number you read in an article, including this one, as a starting estimate to confirm, not a fact to act on.

When to Seek Care Rather Than Continue Self-Managing

LDN prescribing decisions, dose adjustments, and evaluation of side effects should go through your prescriber, not be self-directed from this guide. Seek urgent care rather than waiting for a routine follow-up if you experience signs of opioid withdrawal after starting naltrexone (this suggests recent opioid use was not fully cleared), signs of liver injury such as jaundice, dark urine, or right upper quadrant pain, or any severe or unexpected reaction after starting a new medication.